A Phase 1 interventional study of ABBV-744 and Navitoclax in Myelofibrosis (MF), sponsored by AbbVie. Active, not recruiting at 43 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-16.
Sponsored by AbbVie · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 454 studies in Primary Myelofibrosis with a site in United States — 70 open to participants now, 105 under way, 12 of them phase 3. Primary Myelofibrosis · United States.
Among the 454 studies in Primary Myelofibrosis with a site in United States, this one is the 269th largest by enrollment of the 388 interventional ones that give a count, is one of 15 that started in 2020, is one of 117 in phase 1, reaches primary completion later than 36 of the 104 other live ones, and was the 355th registered.
627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.
Browse Primary Myelofibrosis studies →70 of the 454 studies in Primary Myelofibrosis with a site in United States are open now. Recruiting first, the newest first:
John Mascarenhas · Sites in United States
Ages 18+
Takeda · Sites in United States, Argentina, Australia and 28 more countries
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18–75 · Healthy volunteers
Damora Therapeutics · Sites in United States, Australia
Ages 18+
University of Utah · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
454 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 167 · Phase 2 220 · Phase 3 45
First in 1992; this study’s year is marked. 15 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 43 across 492 interventional studies indexed under Primary Myelofibrosis.
Median enrollment 40 across the 388 interventional studies, 153 across the 35 observational. Of the 328 that completed or were terminated, 152 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
134 of 454 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 360 completed or terminated interventional studies of FDA-regulated products, 216 (60%) have results posted.
AbbVie has 8 studies filed under Primary Myelofibrosis — fewer than ten, so there is no comparison to draw.
40 of the studies in Primary Myelofibrosis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06479135Phase 3Kartos Therapeutics, Inc.Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib | 2026-12-31 |
| NCT06468033Phase 3PharmaEssentiaP1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk | 2027-11-18 |
| NCT02934477Center for International Blood and Marrow Transplant ResearchProspective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis | 2026-11 |
| NCT01973881University of Michigan Rogel Cancer CenterQuantitative MRI for Myelofibrosis | 2026-12 |
| NCT06414681University of Kansas Medical CenterCombination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined | 2026-12 |
Add all 40 to your calendar (.ics) → With an account.
Among the 454 studies in Primary Myelofibrosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Myelofibrosis (MF) is a bone marrow illness that affects blood-forming tissues in the body. MF disturbs the body's normal production of blood cells, causing extensive scarring in the bone marrow. This leads to severe anemia, weakness, fatigue, and an enlarged spleen. The purpose of this study is to see how safe and tolerable ABBV-744 is, when given alone, and in combination with ruxolitinib or navitoclax, for adult participants with MF.
ABBV-744 is an investigational drug being developed for the treatment of MF. The study has 4 segments - A, B, C, and D. In Segment A, the safe dosing regimen of ABBV-744 is identified and then, given alone as monotherapy. In Segment B, C, and D, combination therapies of ABBV-744 with either ruxolitinib or navitoclax are given. Adult participants with a diagnosis of MF will be enrolled. Around 130 participants will be enrolled in 60 sites worldwide.
In Segment A, participants will receive different doses and schedules of oral ABBV-744 tablet to identify safe dosing regimen. Additional participants will be enrolled at the identified monotherapy dosign regimen. In Segment B, participants will receive oral ruxolitinib and ABBV-744 will be given as "add-on" therapy. In Segment C, participants will receive ABBV-744 and oral navitoclax. In Segment D, participants will receive ABBV-744 and ruxolitinib. Participants will receive treatment until disease progression or the participants are not able to tolerate the study drugs.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of treatment will be checked by medical assessments, blood and bone marrow tests, checking for side effects, and completing questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Segment-Specific Prior Therapy Criteria:
Segment A:
Segment B:
At least one of the following criteria (a, b, or c):
\< 24 weeks duration of current ruxolitinib course with documented resistance, refractories, or loss of response, as defined by any of the following:
Prior treatment with ruxolitinib for >= 28 days complicated by any of the following:
Segment C:
Exclusion Criteria:
Segment-Specific Prior Therapy Criteria:
Segment A:
Segment B:
Segment C:
Segment D:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who have been previously treated with Janus Kinase inhibitor(s) (JAKi) and stopped such therapy, will receive different dosing regimens and schedules of ABBV-744 to identify the safe dosing regimen and schedule.
Drug: ABBV-744
Participants will receive the identified safe dosing regimen of ABBV-744 as monotherapy.
Drug: ABBV-744
Participants whose disease (myelofibrosis) is inadequately controlled by ongoing ruxolitinib therapy will receive ruxolitinib and ABBV-744 as "add-on" therapy.
Drug: ABBV-744 · Drug: Ruxolitinib
Participants who have previously been exposed to JAKi, and stopped such therapy, will receive ABBV-744 and navitoclax.
Drug: ABBV-744 · Drug: Navitoclax
Participants who have never received JAKi will receive ABBV-744 and ruxolitinib.
Drug: ABBV-744 · Drug: Ruxolitinib
Tablet; Oral
Tablet; Oral
Also known as: ABT-263
Tablet; Oral
Percentage of Participants With Adverse Events
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug.
Time frame: Up to Approximately 1 year from start of study
Percentage Of Participants Who Achieve Spleen Volume Reduction Of 35% Or Greater (SVR35)
Reduction in spleen volume is measured by magnetic resonance imaging (MRI) or computed tomography (CT) scan.
Time frame: Up To Week 24
Maximum Observed Plasma Concentration (Cmax) of ABBV-744
Maximum observed plasma concentration (Cmax) of ABBV-744.
Time frame: Up To Week 12
Time To Cmax (Tmax) Of ABBV-744
The amount of time taken to reach Cmax.
Time frame: Up To Week 12
Area Under The Concentration Versus Time Curve (AUC) Of ABBV-744
AUC of ABBV-744 will be calculated.
Time frame: Up To Week 12
Half-Life (t1/2) Of ABBV-744
Half-life of ABBV-744 will be calculated.
Time frame: Up To Week 12
Accumulation Ratio Of ABBV-744
Pharmacokinetic parameters will include accumulation ratio of ABBV-744.
Time frame: Up To Week 12
Apparent Clearance (CL/F) Of ABBV-744
CL/F of ABBV-744 will be calculated.
Time frame: Up To Week 12
Apparent Volume Of Distribution (Vd/F) Of ABBV-744
Vd/F of ABBV-744 will be calculated.
Time frame: Up To Week 12
Percentage Of Participants With >= 50% Reduction In Total Symptom Score (TSS)
TSS is assessed using the Myelofibrosis Symptom Assessment Form (MFSAF) v4.0. MFSAF v4.0 measures the burden of myelofibrosis-related symptoms. The symptoms are assessed on a 11-point numeric rating scale (NRS) anchored from 0 (absent) to 10 (worst imaginable).
Time frame: Up to Week 24
Objective Response Rate (ORR)
ORR is defined as the sum of rates of partial remission (PR) or better.
Time frame: Week 24
Maximum Observed Plasma Concentration (Cmax) Of Navitoclax
Maximum Observed Plasma Concentration (Cmax) Of Navitoclax.
Time frame: Up To Week 12
Time To Cmax (Tmax) Of Navitoclax
The amount of time taken to reach Cmax.
Time frame: Up To Week 12
Area Under The Concentration Versus Time Curve (AUC) Of Navitoclax
AUC of Navitoclax will be calculated.
Time frame: Up To Week 12
Maximum Observed Plasma Concentration (Cmax) Of Ruxolitinib
Maximum Observed Plasma Concentration (Cmax) Of Ruxolitinib.
Time frame: Up To Week 12
Time To Cmax (Tmax) Of Ruxolitinib
The amount of time taken to reach Cmax.
Time frame: Up To Week 12
Area Under The Concentration Versus Time Curve (AUC) Of Ruxolitinib
AUC of Ruxolitinib will be calculated.
Time frame: Up To Week 12
Plan to share: No
Started Nov 2020 (actual). Primary completion is estimated for Jan 2027, 74 months after the start.
Of 68 phase 1 interventional studies under Primary Myelofibrosis, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 103. This study's planned 74 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.